Do we really know the prevalence of multi-drug resistant Escherichia coli in the territorial and nosocomial population?

Urology Annals

Volumn 5, Issue 1, 2013, Pages 25-29

  Picozzi, Stefano ^a   Ricci, Cristian ^b   Gaeta, Maddalena ^b   MacChi, Alberto ^a   Dinang, Emmanuel ^a   Paola, Gaia ^b   Tejada, Milvana ^b   Costa, Elena ^b   Bozzini, Giorgio ^a   Casellato, Stefano ^a   Carmignani, Luca ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Escherichia coli; hospital; resistance; territory; urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFAZOLIN; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CATCHMENT; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE;

EID: 84875699518     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.106962     Document Type: Article

References (15)

1. Stamm WE. The epidemiology of urinary tract infections: Risks factors reconsidered. Inter Sci Conf Antimicrob Agents Chemother 1999;39:769.
2. Bearden DT, Danziger LH. Mechanism of action of and resistance to quinolones. Pharmacotherapy 2011;21:224S-32S.
3. Caccamo M, Perilli M, Celenza G, Bonfiglio G, Tempera G, Amicosante G. Occurrence of extended spectrum beta-lactamases among isolates of Enterobacteriaceae from urinary tract infections in southern Italy. Microb Drug Resist 2006;12:257-64.
4. Carattoli A, García-Fernández A, Varesi P, Fortini D, Gerardi S, Penni A, et al. Molecular epidemiology of Escherichia coli producing extended-spectrum beta-lactamases isolated in Rome, Italy. J Clin Microbiol 2008;46:103-8.
5. Yagci D, Yoruk F, Azap A, Memikoglu O. Prevalence and risk factors for selection of quinolone-resistant Escherichia coli strains in fecal flora of patients receiving quinolone therapy. Antimicrob Agents Chemother 2009;53:1287-9.
6. Diekema, DJ, BootsMiller BJ, Vaughn TE, Woolson RF, Yankey JW, Ernst EJ, et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals Clin Infect Dis 2004;38:78-85.
7. Viray, M, Linkin D, Maslow JN, Stieritz DD, Carson LS, Bilker WB, Lautenbach E. Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: Emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol 2005;26:56-62.
8. Boyd LB, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect Dis 2008;8:4.
9. Heisig P. Genetic evidence for a role of ParC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 1996;40:879-85.
10. Rossi F, Baquero F, Hsueh PR, Paterson DL, Bochicchio GV, Snyder TA, et al. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother 2006;58:205-10.
11. Gagliotti C, Balode A, Baquero F, Degener J, Grundmann H, Gür D, et al. EARS-Net Participants (Disease Specific Contact Points for AMR). Escherichia coli and Staphylococcus aureus: Bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill 2011;16:19819.
12. Bradford PA. Extended-spectrum beta-lactamases in the 21 st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
13. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006;57:780-3.
14. Ortega M, Marco F, Soriano A, Almela M, Martínez JA, Muñoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: Predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568-74.
15. Azap OK, Arslan H, Serefhanolu K, Colakolu S, Erdoan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16:147-51.